Fameglow Holdings Forms HK$50 Million Anti-Ageing Joint Venture with Nagawa Pharmaceutical and Mirxes
Fameglow Holdings Limited has formed a joint venture with NAGAWA Pharmaceutical and Mirxes, establishing a company in Hong Kong with a capital of HK$50 million. Fameglow will own 75%, NAGAWA 20%, and Mirxes 5%. The venture will focus on anti-ageing products in Hong Kong and selected Asia-Pacific countries. This is a discloseable transaction under GEM Listing Rules, not requiring shareholder approval.
Fameglow Holdings Limited has announced the formation of a joint venture company with NAGAWA Pharmaceutical Co., Ltd. and Mirxes Pte Ltd. The new joint venture, to be established in Hong Kong with a registered capital of HK$50 million, will be owned 75% by Fameglow, 20% by NAGAWA Pharmaceutical, and 5% by Mirxes Pte Ltd. The joint venture will focus on the research, development, and sales of anti-ageing products and solutions in Hong Kong and selected Asia-Pacific countries. This transaction is classified as a discloseable transaction under the GEM Listing Rules but does not require shareholders’ approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fameglow Holdings Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
